Your session is about to expire
← Back to Search
Eribulin Mesylate for Advanced Bladder Cancer
Study Summary
This trial looks at the effect of eribulin mesylate on patients with cancer of the urothelium that has spread to nearby tissue or to other places in the body and kidney dysfunction.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My doctor expects me to live more than 6 months.I am HIV-negative or if positive, not on antiretroviral therapy and have a CD4+ count > 500/mm3.My bladder cancer cannot be removed with surgery and has spread.My cancer is confirmed to be urothelial carcinoma.I am not pregnant or breastfeeding if I am to be treated with E7389.I have previously been treated with eribulin.I've had platinum-based chemo for my advanced or recurrent cancer and also had a tubulin inhibitor.I have a tumor that can be measured with a scan.My medication use will be reviewed to ensure it doesn't interfere with the trial drug.I am a woman willing to join drug level studies, with or without previous treatments.I agree to use birth control during the study due to unknown effects on fetuses.I have had up to two chemotherapy treatments for my advanced disease.My kidney function is either normal or moderately to severely reduced.I do not have untreated or worsening brain metastasis.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I can take care of myself but may not be able to do heavy physical work.
- Group 1: Treatment (eribulin mesylate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In which geographical areas is this experiment taking place?
"Patients can enrol for this trial at various locations, including the University of Michigan Comprehensive Cancer Center in Ann Arbor, City of Hope Antelope Valley in Lancaster and Decatur Memorial Hospital in Decatur. Additionally, there are 24 other medical centres that have active recruitment processes underway."
To what extent is enrollment being sought for this medical research?
"This clinical trial is no longer open for recruitment. It was initially posted on October 23rd, 2006 but had its last update on July 16th 2022. For those still seeking trials to participate in, there are 2502 studies recruiting patients with advanced urothelial carcinoma and 37 pharmacological research projects actively admitting participants."
Could you please summarize any other research initiatives that have been conducted to explore the effects of Pharmacological Study?
"The first Pharmacological Study was conducted in 2006 at the DuPage Medical Group - Joliet facility. To date, there have been 680 completed clinical trials, while 37 are currently ongoing with many located in Ann Arbor, Michigan."
Are there any opportunities for potential participants to join this research?
"At this moment, patients are not being sought for recruitment into the clinical trial. This evaluation was initially posted on October 23rd 2006 and last updated July 16th 2022. For those looking to join other studies, there are presently 2502 medical trials in search of participants with advanced urothelial carcinoma as well as 37 pharmacological experiments recruiting volunteers."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger